Exscientia Ltd ADR

NASDAQ EXAI

Data sourced from

and

Download Data

Exscientia Ltd ADR Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2024: GBP 239.49 M

Exscientia Ltd ADR Shareholders' Equity is GBP 239.49 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -46.51% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Exscientia Ltd ADR Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2023 was GBP 447.72 M, a -38.38% change year over year.
Exscientia Ltd ADR Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2022 was GBP 726.57 M, a 412.74% change year over year.
Exscientia Ltd ADR Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2021 was GBP 141.70 M, a 868.53% change year over year.
Exscientia Ltd ADR Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2020 was GBP 14.63 M, a 165.36% change year over year.

NASDAQ: EXAI

Exscientia Ltd ADR

CEO	Prof. Andrew L. Hopkins DPHIL, FRSE FRSC
IPO Date	Oct. 1, 2021
Location	United Kingdom
Headquarters	The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE
Employees	483
Sector	Healthcare
Industry	Biotechnology

Description

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key trends